Characterization of Nanoparticles Intended for Drug Delivery

<p>Evaluating Nanomedicines: Obstacles and Advancements.-&nbsp;Detection of Bacterial Contamination in Nanoparticle Formulations by Agar Plate Test.-&nbsp;Considerations and Some Practical Solutions to Overcome Nanoparticle Interference with LAL Assays and to Avoid Endotoxin Contamination in Nanoformulations.-&nbsp;Elemental Analysis in Biological Matrices Using ICP-MS.-&nbsp;PEG Quantitation Using Reversed Phase High Performance Liquid Chromatography and Charged Aerosol Detection.-&nbsp;Quantitation of Surface Coating on Nanoparticles Using Thermogravimetric Analysis.-&nbsp;Immunoelectron Microscopy for Visualization of Nanoparticles.-&nbsp;Imaging of Liposomes by Transmission Electron Microscopy.- Updated Method for In Vitro Analysis of Nanoparticle Hemolytic Properties.-&nbsp;In Vitro Assessment of Nanoparticle Effects on Blood Coagulation.-&nbsp;In Vitro Analysis of Nanoparticle Effects on the Zymosan Uptake by Phagocytic Cells.-&nbsp;Assessing NLRP3 Inflammasome Activation by Nanoparticles.-&nbsp;Analysis of Complement Activation by Nanoparticles.-&nbsp;Methods for Analysis of Nanoparticle Immunosuppressive Properties In Vitro and In Vivo.-&nbsp;Analysis of Pro-Inflammatory Cytokine and Type II Interferon Induction by Nanoparticles.-&nbsp;Analysis of Nanoparticle Adjuvant Properties In Vivo.-&nbsp;In Vitro and In Vivo Methods for Analysis of Nanoparticle Potential to Induce Delayed Type Hypersensitivity Reactions.-&nbsp;Autophagy Monitoring Assay II: Imaging Autophagy Induction in LLC-PK1 Cells Using GFP-LC3 Protein Fusion Construct.-&nbsp;Improved Ultrafiltration Method to Measure Drug Release from Nanomedicines Utilizing a Stable Isotope Tracer.-&nbsp;Designing an In Vivo Efficacy Study of Nanomedicines for Preclinical Tumor Growth Inhibition.</p>